Treating anti-PD-1 therapy prophylactically in NASH-mice increased CD8+PD1+ T-cells, aggravated liver damage and heightened the incidence of HCC. The gene discussed is CD8A; the disease is metabolic dysfunction-associated steatohepatitis.